Your browser doesn't support javascript.
Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa.
Anjorin, AbdulAzeez Adeyemi; Odetokun, Ismail A; Nyandwi, Jean Baptiste; Elnadi, Hager; Awiagah, Kwame Sherrif; Eyedo, Joseph; Abioye, Ajibola Ibraheem; Gachara, George; Maisara, Aala MohmedOsman; Razouqi, Youssef; Yusuf Mohamud, Mohamed Farah; Mhgoob, Zuhal Ebrahim; Ajayi, Tunde; Ntirenganya, Lazare; Saibu, Morounke; Salako, Babatunde Lawal; Elelu, Nusirat; Wright, Kikelomo Ololade; Fasina, Folorunso O; Mosbah, Rasha.
  • Anjorin AA; Department of Microbiology (Virology Research), Lagos State University, Ojo 102101, Lagos, Nigeria.
  • Odetokun IA; Department of Veterinary Public Health & Preventive Medicine, University of Ilorin, Ilorin 200213, Kwara State, Nigeria.
  • Nyandwi JB; Department of Pharmacy, University of Rwanda, Kigali 4285, Rwanda.
  • Elnadi H; Infectious Diseases and One Health Department, Universite de Tours, 37000 Tours, France.
  • Awiagah KS; Training and Research Unit, Korle Bu Teaching Hospital, Accra P.O. Box KB 77, Ghana.
  • Eyedo J; Department of Microbiology (Virology Research), Lagos State University, Ojo 102101, Lagos, Nigeria.
  • Abioye AI; Department of Nutrition, Harvard University, Boston, MA 01451, USA.
  • Gachara G; Department of Medical Laboratory Science, Kenyatta University, Nairobi 00609, Kenya.
  • Maisara AM; Department of Nephrology and Hemodialysis Center, Bahre Teaching Hospital and Faculty of Medicine, International University of Africa, Khartoum 12223, Sudan.
  • Razouqi Y; Laboratory of Biological Engineering, Faculty of Science and Technology, Sultan Moulay Slimane University, Mghilla Campus, BP 523, Beni Mellal 23000, Morocco.
  • Yusuf Mohamud MF; Mogadishu Somali Turkish Training and Research Hospital, Mogadishu 2526, Somalia.
  • Mhgoob ZE; Department of Infection Control, Al Jawad Hospital, Khartoum 11111, Sudan.
  • Ajayi T; Lagos State Ministry of Health, Ikeja 100271, Lagos, Nigeria.
  • Ntirenganya L; Pharmacovigilance and Safety Monitoring Division, Rwanda Food and Drugs Authority, Kigali P.O. Box 1948, Rwanda.
  • Saibu M; Department of Biochemistry, Lagos State University, Ojo 102101, Lagos, Nigeria.
  • Salako BL; Walter Sisulu University, Mthatha Campus, Mthatha 5117, South Africa.
  • Elelu N; Department of Medicine, University of Ibadan, Ibadan 200132, Oyo State, Nigeria.
  • Wright KO; Office of the Director General, Nigerian Institute of Medical Research, Yaba, Lagos 101212, Lagos, Nigeria.
  • Fasina FO; Department of Veterinary Public Health & Preventive Medicine, University of Ilorin, Ilorin 200213, Kwara State, Nigeria.
  • Mosbah R; Kwara State COVID-19 Technical Working Group, Ilorin 240241, Kwara State, Nigeria.
Vaccines (Basel) ; 10(4)2022 Apr 01.
Article in English | MEDLINE | ID: covidwho-1776371
ABSTRACT
Local, national, and international health agencies have advocated multi-pronged public health strategies to limit infections and prevent deaths. The availability of safe and effective vaccines is critical in the control of a pandemic. Several adverse events have been reported globally following reception of different vaccines, with limited or no data from Africa. This cross-sectional epidemiological study investigated adverse events following COVID-19 vaccination in Africans from April-June, 2021 using a structured online questionnaire. Out of 1200 participants recruited, a total of 80.8% (n = 969) respondents from 35 countries, including 22 African countries and 13 countries where Africans live in the diaspora, reported adverse events. Over half of the vaccinees were male (53.0%) and frontline healthcare workers (55.7%), respectively. A total of 15.6% (n = 151) reported previous exposure to SARS-CoV-2, while about one-fourth, 24.8% (n = 240), reported different underlying health conditions prior to vaccination. Fatal cases were 5.1% (n = 49), while other significant heterogenous events were reported in three categories very common, common, and uncommon, with the latter including enlarged lymph nodes 2.4% (n = 23), menstrual disorder 0.5% (n = 5), and increased libido 0.2% (n = 2). The study provided useful data for concerned authorities and institutions to prepare plans that will address issues related to COVID-19 vaccines.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Qualitative research / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10040546

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Qualitative research / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10040546